We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Biopharmaceutical company Repligen Corp. and Stanley
Medical Research Institute entered a development agreement that gives Repligen
funding for a Phase I clinical trial for a treatment of bipolar disorder, the
company announced.
Pharmaceutical firms have yet to fully understand the implications of the Medicare
Rx drug benefit, say experts who urge drugmakers to develop compliance strategies
around the new regulations requiring the disclosure of drug pricing.
Generic painkiller hydrocodone (with APAP) was the most frequently prescribed
drug in the U.S. last year -- one of six generic drugs to crack NDCHealth's
top 10 list of pharmaceutical products.
Despite strong protests from the generics industry
and some lawmakers, brand firms' use of authorized generics to extend the profitability
of drugs coming off patent is a trend that will continue to grow, according
to a new research report.
The growing use of IT in the healthcare system -- including through electronic
prescribing and electronic medical records -- could significantly boost
the FDA's ability to monitor drug safety, according to a top agency official.
Endo Pharmaceuticals Holdings licensed Durect's pain patch for an upfront fee
of $10 million, and said it lowered its 2005 adjusted earnings guidance to reflect
higher research and development costs.
The law firm of Schatz & Nobel, which has significant experience representing
investors in prosecuting claims of securities fraud, announces that a lawsuit
seeking class action status has been filed in the United States District Court
for the Western District of Washington on behalf of all persons who purchased
the publicly traded securities of Cell Therapeutics between June 7, 2004, and
March 4, 2005, inclusive.
MDS and Atomic Energy of Canada Limited (AECL) announced that the two companies
have reached an agreement to seek a mediated resolution of the issues related
to the construction, commissioning and operation of the MAPLE facilities in
Chalk River, Ontario.
Shareholders in Hoechst AG are trying to block Sanofi-Aventis SA's acquisition
of the remaining shares it does not own in the company, a spokesman for Sanofi-Aventis
said.